References
- Michael J. Thirman and Richard A. Larson (1996). “Therapy-related myeloid leukemia”. In: Stephen D. Nimer and David W. Golde (Eds.) Hematologic Complications of Cancer. Hematology/Oncology Clinics of North America, 10, 293–320.
- Larson, R. A., Banerjee, M., Wang, Y., Wiemels, J., Hartford, C., Le Beau, M. M. and Smith, M. T. (1997). “An inactivating polymorphism in the NAD(P)H: Quinone oxidoreductase (NQOl) gene in patients with primary and therapy-related myeloid leukemia(t-AML). “Proc. Am. Soc. Clin. Oncol., 16, 530a (abstract #1911).
- Le Beau, M. M., Albain, K. S., Larson, R. A. et al. (1986). Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J. Clin. Oncol., 4, 325–345.
- Levine, E. G. and Bloomfield, C. D. (1992). Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin. Oncol., 19, 471.
- Hayes, R. B., Yin, S. N., Dosemeci, M. et al. (1997). Benzene and the dose-related incidence of hematologic neoplasms in China. J. Natl. Cancer Inst., 89, 1065–1071.
- Pedersen-Bjergaard, J. and Rowley, J. D. (1994). The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood, 83(10), 2780–2786.